The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer

IntroductionLoss of the retinoblastoma protein tumor suppressor gene (RB) coding for a nuclear phosphoprotein that regulates the cell cycle is found in many human cancers and probably leads to disruption of the p16-cyclin D1-CDK4/6-RB pathway. Cyclin D1 is known to activate CDK4, which then phosphorylates the RB protein, leading to cell cycle progression. p16 inhibits CDK4, keeping RB hypophosphorylated and preventing cell cycle progression. The significance of these three markers, cyclin D1, CDK4 and p16, for breast cancer and carcinogenesis is nevertheless still controversial.MethodsThe material consisted of 102 formalin-fixed human breast cancer samples, in which cyclin D1, CDK4 and p16 expression was evaluated immunohistochemically. The amounts of cyclin D1 mRNA present were analyzed by quantitative real time PCR.ResultsHigh cyclin D1 expression statistically significantly correlated with lower tumor grade, estrogen and progesterone receptor positivity and lower proliferation activity in breast tumors and increased breast cancer-specific survival and overall survival. Tumors with high cyclin D1 protein had 1.8 times higher expression of cyclin D1 mRNA. CDK4 expression did not correlate with cyclin D1 expression or the survival data. p16 expression was associated with Human Epidermal Growth Factor Receptor 2 (HER2) negativity and increased breast cancer-specific survival and disease-free survival. No statistical correlations between cyclin D1, CDK4 and p16 were found.ConclusionsCyclin D1 was associated with a good breast cancer prognosis but functioned independently of CDK4. High cyclin D1 expression may be partially due to increased CCND1 transcription. p16 correlated with a better prognosis and may function without CDK4. In conclusion, it appears that cyclin D1, CDK4 and p16 function independently in human breast cancer.

• Publication year

  2013

• Venue

  Breast Cancer Research

• Publication date

  2013-01-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/bcr3376PMID 23336272PMCID 3672746
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer

  2013cited by this paper
• Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients

  2012cited by this paper
• risk human papilloma virus associated oropharynx squamous cells carcinomas : Clinical , iological implications and therapeutical perspectives

  2012cited by this paper
• [High-risk human papilloma virus associated oropharynx squamous cell carcinomas: clinical, biological implications and therapeutical perspectives].

  2012cited by this paper
• Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study

  2012cited by this paper
• Immunomarkers in Gynecologic Cytology: The Search for the Ideal ‘Biomolecular Papanicolaou Test’

  2012cited by this paper
• Prolyl Hydroxylase PHD3 Enhances the Hypoxic Survival and G1 to S Transition of Carcinoma Cells

  2011cited by this paper
• Cyclin D as a therapeutic target in cancer

  2011influential reference
• Overexpressions of Cyclin B1, cdc2, p16 and p53 in Human Breast Cancer: The Clinicopathologic Correlations and Prognostic Implications

  2011cited by this paper
• The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments.

  2011cited by this paper
• Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer.

  2011cited by this paper
• Rb inactivation in cell cycle and cancer: The puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase

  2010cited by this paper
• p16 Modulates VEGF Expression via Its Interaction With HIF-1α in Breast Cancer Cells

  2010cited by this paper
• p16 expression in basal-like breast carcinoma

  2010cited by this paper
• Requirement of Cdk4 for v-Ha-ras-Induced Breast Tumorigenesis and Activation of the v-ras-Induced Senescence Program by the R24C Mutation.

  2010cited by this paper
• p16INK4a expression in basal-like breast carcinoma.

  2010cited by this paper
• Testing for HER2 in Breast Cancer: A Continuing Evolution

  2010cited by this paper
• Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells—identification of a novel androgen response element

  2010cited by this paper
• Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors

  2009cited by this paper
• Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy

  2008cited by this paper
• The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas

  2008cited by this paper
• p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ.

  2008cited by this paper
• Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.

  2008cited by this paper
• Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression

  2007cited by this paper
• Cdk1 is sufficient to drive the mammalian cell cycle

  2007cited by this paper
• CDK4 Inhibitors and Apoptosis: A Novel Mechanism Requiring Nucleolar Targeting of RelA

  2007cited by this paper
• Cyclin D1 and breast cancer.

  2006influential reference
• World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs

  2005cited by this paper
• Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis.

  2005cited by this paper
• Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.

  2005cited by this paper
• The Retinoblastoma Protein and Cell Cycle Control Review

  2004influential reference
• Interlaboratory Comparison of HER-2 Oncogene Amplification as Detected by Chromogenic and Fluorescence in situ Hybridization

  2004cited by this paper
• G1 cell-cycle control and cancer

  2004cited by this paper
• A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer.

  2003cited by this paper
• Hypoxia stimulates p16 expression and association with cdk4.

  2002cited by this paper
• Overexpression of the p16 Cell Cycle Inhibitor in Breast Cancer is Associated with a More Malignant Phenotype

  2001cited by this paper
• p16(MTS-1/CDKN2/INK4a) in cancer progression.

  2001cited by this paper
• Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone.

  2000cited by this paper
• Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation.

  1999cited by this paper
• Cancer Cell Cycles

  1996influential reference
• Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16

  1995cited by this paper
• The retinoblastoma protein and cell cycle control.

  1995cited by this paper
• Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia.

  1994cited by this paper
• Expression and amplification of cyclin genes in human breast cancer.

  1993cited by this paper

• The Relationship of CDK4 Expression with Histopathological Grade and Metastasis in Luminal Subtype Breast Cancer

  2026cites this paper
• The dual role of cyclin D1: Unraveling its tumor-promoting mechanisms and opportunities for therapeutics.

  2025cites this paper
• Innovative Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with Various Pathway Signaling

  2025cites this paper
• Novel furanone-based anticancer agents: Design, synthesis, Hsp90 inhibition, in vivo antitumor activity and pharmacokinetic studies.

  2025cites this paper
• Mechanism and Predictive Role of NUB1 Protein in Oestrogen Receptor Pathway of FEC-Treated Breast Cancer Patients

  2025cites this paper
• Semisynthesis of Novel Alicyclic Triterpene-Triazole Derivatives from Boswellia sacra Gum Resin: Potential Anti-breast Cancer and Immunomodulatory Effects on T‑Cell Activation

  2025cites this paper
• AFFECT: an R package for accelerated functional failure time model with error-contaminated survival times and applications to gene expression data

  2024cites this paper
• Specificity of U2 and GOL1 aptamers to EGFR-positive human glioblastoma cells in vitro

  2024cites this paper
• Immunohistochemical Expression of Cyclin D1 and p16 in Invasive Breast Carcinoma and Its Association with Clinicopathological Parameters

  2024cites this paper
• GeneSurv: Multi-Gene Cancer Survival Analysis Tool

  2024cites this paper
• Modulation of tumor plasticity by senescent cells: Deciphering basic mechanisms and survival pathways to unravel therapeutic options

  2024cites this paper
• Expression of Cyclin D1 and Claudin-1 in Invasive Breast Carcinoma and Their Correlation with Clinicopathological Parameters

  2024cites this paper
• Panobinostat Synergizes with Chemotherapeutic Agents and Improves Efficacy of Standard-of-Care Chemotherapy Combinations in Ewing Sarcoma Cells

  2024cites this paper
• AteMeVs: An R package for the estimation of the average treatment effect with measurement error and variable selection for confounders

  2024cites this paper
• Specificity of Aptamers U2 and Gol1 to EGFR-Positive Human Glioblastoma Cells in Vitro

  2024cites this paper
• CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2- advanced breast cancer: a phase III RCTs based meta-analysis

  2024cites this paper
• P16 Expression in Human Breast Carcinoma and its Relationship to Clinicopathological Parameters

  2023cites this paper
• Identification and validation of the cellular senescence-related molecular subtypes of triple negative breast cancer via integrating bulk and single-cell RNA sequencing data.

  2023cites this paper
• Chemopreventive approach of Indian spice “Curcumin” in the treatment of breast cancer

  2023cites this paper
• Update on clinical characteristics and molecular insights for uterine intravenous leiomyomatosis (Review)

  2023cites this paper
• Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab.

  2023cites this paper
• EZH2 as a therapeutic target for aggressive prostate cancer

  2023cites this paper
• The Prognostic Significance of P16 Immunohistochemical Expression Pattern in Women with Invasive Ductal Breast Carcinoma.

  2023cites this paper
• Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.

  2023cites this paper
• Differences and Similarities between Colorectal Cancer Cells and Colorectal Cancer Stem Cells: Molecular Insights and Implications

  2023cites this paper
• Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today?

  2023cites this paper
• Abemaciclib-loaded ethylcellulose based nanosponges for sustained cytotoxicity against MCF-7 and MDA-MB-231 human breast cancer cells lines

  2022cites this paper
• The histidine phosphatase LHPP: an emerging player in cancer

  2022cites this paper
• Clinical Correlation and Role of Cyclin D1 Expression in Glioblastoma Patients: A Study From North India

  2022cites this paper
• p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer.

  2022cites this paper
• Molecular investigation of mechanisms considered to cause preterm premature membrane rupture

  2022cites this paper
• Immunohistochemical Overexpression of Cyclin D1 in Tunisian Invasive Breast Carcinoma Women

  2022cites this paper
• High prevalence of p16 staining in malignant tumors

  2022cites this paper
• Complex cross-talk between EZH2 and miRNAs confers hallmark characteristics and shapes the tumor microenvironment.

  2022cites this paper
• p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer

  2022cites this paper
• LNX1 Contributes to Cell Cycle Progression and Cisplatin Resistance

  2021cites this paper
• Review of novel tissue-based biomarkers for prostate cancer: towards personalised and targeted medicine

  2021cites this paper
• OTT_A_309091 3309..3318

  2021cites this paper
• The Role of CDK4 in the Pathogenesis of Pancreatic Cancer

  2021cites this paper
• Breast Cancer and p16: Role in Proliferation, Malignant Transformation and Progression

  2021cites this paper
• Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer

  2021cites this paper
• Impact of circulating miRNA-373 on breast cancer diagnosis through targeting VEGF and cyclin D1 genes

  2021cites this paper
• δ-Tocotrienol induces apoptosis and inhibits proliferation of nasopharyngeal carcinoma cells.

  2021cites this paper
• Inhibition of angiotensin II type 1 receptor by candesartan reduces tumor growth and ameliorates fibrosis in colorectal cancer

  2021cites this paper
• Review of novel liquid-based biomarkers for prostate cancer: towards personalised and targeted medicine

  2021cites this paper
• Chaperonin-Containing TCP1 Complex (CCT) Promotes Breast Cancer Growth Through Correlations With Key Cell Cycle Regulators

  2021cites this paper
• Coiled-Coil Domain-Containing 68 Downregulation Promotes Colorectal Cancer Cell Growth by Inhibiting ITCH-Mediated CDK4 Degradation

  2021cites this paper
• The prognostic value of cyclin D1 in breast cancer patients treated with hormonal therapy: A pilot study.

  2021cites this paper
• A Phase I/Ib Trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-Positive Advanced Breast Cancer After Trastuzumab and Taxane Therapy.

  2021cites this paper
• Steroid Hormone Receptors: Links With Cell Cycle Machinery and Breast Cancer Progression

  2021cites this paper
• Angiotensin receptor blocker Losartan inhibits tumor growth of colorectal cancer

  2021cites this paper
• Bioinformatics Study of Sea Cucumber Peptides as Antibreast Cancer Through Inhibiting the Activity of Overexpressed Protein (EGFR, PI3K, AKT1, and CDK4)

  2021cites this paper
• Diagnosis of Melanoma Disease State From Patient Blood Samples Using Photoacoustic Flow Cytometry

  2021cites this paper
• Cyclin D1 and PSA act as good prognostic and clinicopathological indicators for breast cancer

  2020cites this paper
• A semi-automated workflow for adverse outcome pathway hypothesis generation: The use case of non-genotoxic induced hepatocellular carcinoma.

  2020cites this paper
• Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments

  2020cites this paper
• Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model

  2020cites this paper
• The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer

  2020cites this paper
• Quantification of DNA and AgNORs correlating to cyclin D1-immunoexpression in human breast cancer

  2020cites this paper
• HTLV-1 Tax Stimulates Molecular Events in Various Cancers

  2020cites this paper
• Molecular binding signatures of Trigonella foenum-graecum compounds on cyclin-dependent kinase 4 for possible anti-cancer mechanism in breast cancer

  2020influential citation
• Constitutive expression of progesterone receptor isoforms promotes the development of hormone-dependent ovarian neoplasms

  2020cites this paper
• Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors

  2020cites this paper
• Immunohistochemical expression of cyclin D1 in invasive breast carcinoma and its correlation with clinicopathological parameters

  2020cites this paper
• Cancer cell reprogramming: a promising therapy converting malignancy to benignity

  2019cites this paper
• The novel chromatin architectural regulator SND1 promotes glioma proliferation and invasion and predicts the prognosis of patients.

  2019cites this paper
• Quercetin protects PC-12 cells against hypoxia injury by down-regulation of miR-122

  2019cites this paper
• Transcriptional Regulation of Non-Coding RNAs by Retinoblastoma Tumor Suppressor Protein

  2019influential citation
• Transcriptional Regulation of Non-Coding RNAs by Retinoblastoma Tumor Suppressor Protein

  2019influential citation
• Gene expression association study in feline mammary carcinomas

  2019cites this paper
• Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies

  2019cites this paper
• Biological rationale for a patient-specific approach in the treatment of breast cancer. Clinical value of novel biomarkers of breast cancer

  2019cites this paper
• Constitutive Expression of the Progesterone Receptor Isoforms Promotes Hormone-Dependent Development of Ovarian Neoplasms

  2019cites this paper
• Effects of Baneh (Pistacia atlantica) Gum on Human Breast Cancer Cell Line (MCF-7) and Its Interaction with Anticancer Drug Doxorubicin

  2019cites this paper
• The prognostic value of cyclin D1 expression in the survival of cancer patients: A meta-analysis.

  2019cites this paper
• Tumor suppressor LHPP regulates the proliferation of colorectal cancer cells via the PI3K/AKT pathway

  2019cites this paper
• Prognostic impact of high p16/cyclin D1 index in breast cancer.

  2019cites this paper
• The Interplay of Proteins Encoded by CDKN1A, CDKN1B, CDKN2A and TP53 in the Prognosis of Breast Cancer

  2019influential citation
• Expression of p16 and SATB1 in Invasive Ductal Breast Cancer – A Preliminary Study

  2018cites this paper
• Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer

  2018cites this paper
• Cancer molecular markers: A guide to cancer detection and management.

  2018cites this paper
• Peptide SA12 inhibits proliferation of breast cancer cell lines MCF-7 and MDA-MB-231 through G0/G1 phase cell cycle arrest

  2018influential citation
• Cyclin D1-mediated microRNA expression signature predicts breast cancer outcome

  2018cites this paper
• Stabilization of Cyclin-Dependent Kinase 4 by Methionyl-tRNA Synthetase in p16INK4a-Negative Cancer.

  2018cites this paper
• Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer

  2018cites this paper
• The Wnt Pathway Components are Upregulated in Different Molecular Subtypes of Invasive Ductal Carcinoma Patients of Breast

  2018cites this paper
• Indonesian Pasuruan propolis extract does not exert antiproliferation and pro-apoptotic effect on human colon carcinoma cell line HT-29

  2018cites this paper
• Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer

  2018cites this paper
• Prognostic Utility of Cyclin D1 in Invasive Breast Carcinoma

  2018cites this paper
• Computational approach for generating robust models for discovering novel molecules as Cyclin Dependent Kinase 4 inhibitors.

  2018cites this paper
• Lentiviral vector-mediated IL-9 overexpression stimulates cell proliferation by targeting c-myc and cyclin D1 in colitis-associated cancer

  2018cites this paper
• Molecular targets of curcumin in breast cancer (Review).

  2018cites this paper
• USP28 Deficiency Promotes Breast and Liver Carcinogenesis as well as Tumor Angiogenesis in a HIF-independent Manner

  2018cites this paper
• Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment

  2018influential citation
• Hormetic dose response to L-ascorbic acid as an anti-cancer drug in colorectal cancer cell lines according to SVCT-2 expression

  2018cites this paper
• Hint1 expression inhibits proliferation and promotes radiosensitivity of human SGC7901 gastric cancer cells

  2018cites this paper
• Curcumin-Loaded Solid Lipid Nanoparticles Enhanced Anticancer Efficiency in Breast Cancer

  2018cites this paper
• Down-regulation of LHPP in cervical cancer influences cell proliferation, metastasis and apoptosis by modulating AKT.

  2018cites this paper
• CDK4/6 inhibitors in HER2-positive breast cancer.

  2017cites this paper
• The prognostic significance of cyclin D1 expression in patients with triple-negative breast cancer.

  2017cites this paper